And Barclays today raised its price target on KITE to $65, maintaining an “equal weight” rating. KITE stock, along with JUNO, look increasingly well poised as biotech stocks to watch in the lymphoma therapeutics market. The market for lymphoma therapeutics, chock-full of treatment opportunities, is expected to grow at a compounded annual growth rate of 3.84% until 2020, with 62% of sales captured in North America. These results bode well for placing Kite Pharma’s treatment among the best of the best. As for patients with TFL and PMBCL, 91% improved and 73% went into complete remission. However, 76% of the 51 patients treated with KTE-C19 improved while showing a remission rate of 47%.
#Kite pharmaceuticals stock trial#
Kite’s phase-2 trial treated 51 patients with a common form of non-Hodgkin lymphoma and 11 patients with transformed follicular lymphoma and primary mediastinal large B-cell lymphoma.
10 Stocks That Should Be in Your Portfolio Right Nowīut KITE stock holders aren’t the only ones dancing in the streets - Juno Therapeutics Inc (NASDAQ: JUNO) is up 12% on today’s news, as Juno offers a similar lymphoma treatment, which came under pressure amid the deaths of two patients in the first half of 2016.Kite, in conjunction with the Leukemia and Lymphoma Society Inc., is championing its lead product, KTE-C19, for regulatory approval in the treatment of patients suffering from diffuse large B-cell lymphoma and other forms of the lymphoid cancer. “We view the 3-month CR rate across the entire ZUMA-1 cohort as favorable and suggestive of a durable response … The ZUMA-1 study pre-defines duration of response as inclusive of all three pt cohorts, and therefore we think the trial should observe a >6 months duration of response which view as a key marker for regulatory approval”
The reason for the move is positive top-line data in its most recent clinical trial for its lymphoma treatment, showing roughly two-thirds of patients responded positively to Kite’s treatment, with 40% going into “complete remission.”Īccording to Jefferies analyst Biren Amin: Today, Kite is trading just shy of $60 a share, trimming its year-to-date loss to just 2.9%. This reading ranks in the 95th percentile of its annual range, pointing toward a very unusual put-skew among options that expire in three months or less.Kite Pharma Inc (NASDAQ: KITE) closed Monday at $54.98, marking an 11% decline for the year for KITE stock owners. Some options traders may have been betting against the possibility of a buyout, based on TRCO's Schaeffer's put/call open interest ratio (SOIR) of 1.25. Tribune Media Co had been gaining on the charts due to the M&A chatter, and today's move puts its 2017 advance at 44.5%. TRCO stock earlier hit an annual high of $43.04, and was last seen up 5.3% at $42.43, after Sinclair Broadcast Group Inc (NASDAQ:SBGI) said it planned to buy Tribune Media in a cash-and-stock deal worth $3.9 billion - or $43.50 per share. Sinclair Buyout Sends Tribune Media to New High Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) reveals a 10-day call/put volume ratio of 5.47 for Gigamon Inc, which ranks in the 78th annual percentile. Options traders are likely cheering today's price action, though. 18, but remain below their year-to-date breakeven point of $45.55. The shares are set for their highest close since Jan. GIMO stock is one of the top gainers on the New York Stock Exchange, adding 17.7% to trade at $41.20, thanks to news hedge fund Elliott Management has taken a roughly 15% stake in the company. Analysts certainly have high expectations for Kite Pharma Inc, with 10 of the 14 covering brokerage firms rating the stock a "buy" or "strong buy." Gigamon Stock Soars on Elliott Management Stake Still, the shares earlier found a floor at their rising 80-day moving average, and still sport a roughly 62% year-to-date lead. KITE stock has landed on the short-sale restricted list today, down 11.2% at $72.60, due to disappointing first-quarter results, and news that a patient died in its lead CAR-T therapy study. Here's a quick look at what's moving shares of KITE, GIMO, and TRCO. Among specific stocks on the move are drug stock Kite Pharma Inc (NASDAQ:KITE), tech issue Gigamon Inc (NYSE:GIMO), and media concern Tribune Media Co (NYSE:TRCO).
stocks are struggling to hold gains this afternoon.
0 kommentar(er)
